“A University of Colorado Cancer Center study published today in the journal Clinical Cancer Research provides an in-depth look at how these ALK+ and ROS1+ cancers evolve to resist treatment. A second study demonstrates the ability to identify these changes in patient blood samples, perhaps easing the ability to monitor patients for these changes that … Continue reading Two Colorado studies find resistance mechanisms in ALK+ and ROS1+ cancers
Since I’ve been holding steady on my treatment, I haven’t needed access to a clinical trial yet. However, clinical trials may become essential to my survival, and I’m already concerned about getting into them when I need help the most. I often hear scientists ask, “how can we increase patient participation in clinical trials so … Continue reading The Unnecessary Cruelty of Clinical Trials by: Lisa Goldman
“Crizotinib (Xalkori) induced a nearly 72% overall response rate and a median progression-free survival of almost 16 months in a single-arm phase II trial of 127 patients with ROS1-positive advanced non–small cell lung cancer (NSCLC).” read full article here
Dr. Sukhmani K. Padda, an assistant professor of medicine at Stanford University, discusses emerging therapeutic strategies for several rare mutations in NSCLC including ROS1. http://www.onclive.com/conference-coverage/mlcc-2018/novel-agents-emerging-for-lesserknown-targets-in-nsclc?p=1
Today the Centers for Medicare and Medicaid announced they will cover Next Generation Sequencing (NGS) for cancer! This is a major victory for all cancer patients. Decision Memo for Next Generation Sequencing (NGS) for Medicare Beneficiaries with Advanced Cancer (CAG-00450N)
Some researchers think combining immunotherapy and certain targeted therapies called tyrosine kinase inhibitors (TKIs) may be too toxic for patients. This Phase 1/2 study supports that idea. It combined nivolumab and full-dose crizotinib in ALK+ non-small cell lung cancer, and was discontinued for safety reasons when 38% of the first 13 patients developed liver problems … Continue reading Should we combine TKIs and immunotherapy?